Role of argatroban infusion in controlling clot formation in post-cardiac surgical extracorporeal membrane oxygenation in pediatrics: A case series of three patients.
Lara Majdi Samhan, Muhammad Shahzad, Ashjan Alghanem et al.
✦ AI-curated · Sources linked
Case in brief
This case series describes three children receiving extracorporeal membrane oxygenation (ECMO) after cardiac surgery who were anticoagulated with argatroban. One was switched from heparin because of suspected heparin-induced thrombocytopenia; the abstract does not specify why argatroban was used in the other two. Doses varied from 0.18 to 2.13 mcg/kg/min, with titration needs differing between patients. All three were successfully decannulated, but complications included arterial and circuit thrombosis and mild intracranial hemorrhage. The authors note that optimal argatroban monitoring strategies remain to be established.
What made this case unusual
The case series highlights markedly variable argatroban dose requirements in pediatric post-cardiac-surgery ECMO, alongside both thrombotic complications and mild intracranial hemorrhage.
Diagnostic / clinical pearl
Argatroban dosing during pediatric ECMO may require substantial individual titration; the authors recommend lower doses in patients with hepatic impairment.
Why it matters
The authors identify optimal monitoring strategies as unresolved, underscoring uncertainty in managing argatroban anticoagulation in this setting.